15 January 2019 in Clinical and Translational Medicine
Pancreatic cancer is one of the leading causes of cancer‐related death in the United States and survival outcomes remain dismal despite significant advances in molecular diagnostics and therapeutics in clinical practice. The microenvironment of pancreatic cancer carries unique features with increased desmoplastic reaction and is infiltrated by regulatory T cells and myeloid‐derived suppressor cells which negatively impact the effector immune cells. Current evidence suggests that stellate cell‐induced hypovascular stroma may have direct effects on aggressive behavior of pancreatic cancer. Preclinical studies suggested improvement in drug delivery to cancer cells with stroma modifying agents. However these findings so far have not been confirmed in clinical trials. In this article, we elaborate current‐state‐of‐the science of the pancreatic cancer microenvironment and its impact on molecular behavior of cancer cells, chemotherapy resistance and druggability of stroma elements in combination with other agents to enhance the efficacy of therapeutic approaches.
1 April 2007 in Clinical Cancer Research
Purpose: High-dose recombinant human interleukin-2 (IL-2) therapy is of clinical benefit in a subset of patients with advanced melanoma and renal cell cancer. Although IL-2 is well known as a T-cell growth factor, its potential in vivo effects on human immunoregulatory cell subsets are largely unexplored.
14 February 2024 in Cancer Discovery
Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors. We determined the antitumor activity of zanidatamab in patient-derived xenograft (PDX) models developed from pretreatment or postprogression biopsies on the first-in-human zanidatamab phase I study (NCT02892123). Of 36 tumors implanted, 19 PDX models were established (52.7% take rate) from 17 patients. Established PDXs represented a broad range of HER2-expressing cancers, and in vivo testing demonstrated an association between antitumor activity in PDXs and matched patients in 7 of 8 co-clinical models tested. We also identified amplification of MET as a potential mechanism of acquired resistance to zanidatamab and demonstrated that MET inhibitors have single-agent activity and can enhance zanidatamab activity in vitro and in vivo. These findings provide evidence that PDXs can be developed from pretreatment biopsies in clinical trials and may provide insight into mechanisms of resistance. Significance: We demonstrate that PDXs can be developed from pretreatment and postprogression biopsies in clinical trials and may represent a powerful preclinical tool. We identified amplification of MET as a potential mechanism of acquired resistance to the HER2 inhibitor zanidatamab and MET inhibitors alone and in combination as a therapeutic strategy. This article is featured in Selected Articles from This Issue, p. 695
20 January 2015 in British Journal of Cancer
Comment on: α-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
9 October 2018 in British Journal of Cancer
We read the interesting paper by Roseweir et al., 1 which explored the biomarker utility of ERK and p38MAPK in colorectal cancer patients carrying a BRAF mutation. The authors identified phosphorylation of ERK and p38MAPK as a surrogate measure to predict better outcome in BRAF-mutant mismatch repair (MMR)-proficient colorectal cancer patients, who were diagnosed with stage III disease. The prognostic value for combined nuclear pERK and p38 score remained significant after multivariate analysis. The authors did not observe this association in MMRdeficient (MMR-D) BRAF-mutant colorectal cancer patients. BRAF mutations in colorectal cancer are strongly associated with CpG Island methylator phenotype (CIMP), which leads to gene silencing due to methylation of promoter areas of certain genes. 2 CIMP phenotype is known to be associated with sporadic microsatellite instability-high (MSI-H) colon cancers due to frequent methylation of MLH-1. 2,3 Approximately 60% of loss of MLH-1 expression loss is attributable to BRAF mutations. 3 To date, several other studies suggested that more than half of the BRAF-mutant colorectal cancer patients carry the MSI-H phenotype due to loss of MLH-1 function, 4-6 particularly in patients with early stage disease. However, in the paper by Roseweir et al., the frequency of MSI-H tumours in BRAF-mutant stage I-III colorectal cancer patients was only 16% (27/165, Figure 2), suggesting this cohort may not represent the general BRAF-mutant colorectal cancer population (as a side note, although the authors reported 165 BRAF-mutant patients, the Kaplan Meier analyses in Figure 2 included a total of 166 patients). Relatively lower incidence of this important subset of patients might have also impacted the multivariate analysis conducted by the authors. Lastly, in the subgroup analysis of colorectal cancer patients, strong nuclear pERK1/2 pattern was significantly (P = 0.01, Table 3) less frequent in patients with MMR-D tumours. The combined nuclear pERK/p38 score was also relatively less detected in MMR-D cases with a borderline statistical significance (P = 0.065, Table 2) suggesting there may be an inverse association between MMR-D status and the pERK/p38 score. Given MMR-D colorectal cancers patients constitute a relatively larger segment of BRAF-mutant patients which is associated with better outcomes due to MSI-H phenotype, 4 reported inverse relation between MSI-H and pERK/p38 score may generate further challenges regarding the applicability of this score.